Scientific Publications

13 June 2022

Clinical Experience with PEGylated Hyaluronic Acid Fillers: A 3-year Retrospective Study

Raffaele Rauso, Giovanni Francesco Nicoletti, Pierfrancesco Bove , Giuseppe M. Rauso, Romolo Fragola, Giorgio Lo Giudice, Nicola Zerbinati


BACKGROUND: Hyaluronic acid fillers are the most used worldwide, thanks to the high biocompatibility and safety profile of HA and it is also the only substance that can be “dissolved” due to the hyaluronidase effect.
AIM: A retrospective clinical evaluation of the outcomes following PEG cross-linked HA-based filler injection was performed.
METHODS: Data were collected from December 2017 to June 2020. A total of 65 patients (12 M, 53 F), age ranging 28–62 year’s old (mean age 42.3), were treated. Exclusion criteria were applied and in accord to treatment plan, were used specific site injections and fillers. Follow-up was evaluated between 6 months and 2 years.
RESULTS: A total of 61 treatments using 124 vials of HA filler crosslinked with PEG were performed.
CONCLUSION: In conclusion, from 2014, HA fillers having PEG as cross-linker agent have been introduced in the european market. Several papers have been published in order to evaluate the features of these fillers, although, to the best of our knowledge, this is the first clinical paper regarding their use.

Keywords: cross-linked HA hydrogels; optical microscopic examination; PEGDE; matrix structure;
cohesivity; rheological properties

Download PDF

Compile the form here to register
Those credentials are not valid!


Subscribe to the newsletter to receive the scientific and training updates from Neauvia

* indicates required
Compile the form here to request a reset
Those credentials are not valid!